Skip to Content


Active Substance: catumaxomab
Common Name: catumaxomab
ATC Code: L01XC09
Marketing Authorisation Holder: Neovii Biotech GmbH
Active Substance: catumaxomab
Status: Withdrawn
Authorisation Date: 2009-04-20
Therapeutic Area: Ascites Cancer
Pharmacotherapeutic Group: Other antineoplastic agents

Therapeutic Indication

Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

The marketing authorisation for Removab has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.